We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.96%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$783M
AUM Growth
+$86.9M
Cap. Flow
+$43.3M
Cap. Flow %
5.53%
Top 10 Hldgs %
30.88%
Holding
120
New
12
Increased
45
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$13.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.8M
3
GKOS icon
Glaukos
GKOS
+$11.5M
4
AGN
Allergan plc
AGN
+$11.2M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$14.2M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$13.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$11.6M
4
NVCR icon
NovoCure
NVCR
+$10.8M
5
BIIB icon
Biogen
BIIB
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Financials 1.39%
3 Technology 0.15%
4 Energy 0.13%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIVV
76
DELISTED
Bioverativ Inc. Common Stock
BIVV
$2M 0.25%
35,000
+4,000
+13% +$234K
RARX
77
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.75M 0.22%
+119,697
New +$1.81M
STAA icon
78
STAAR Surgical
STAA
$1.21B
$1.12M 0.14%
90,000
+20,050
+29% +$224K
LUMO
79
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.02M 0.13%
+11,111
New +$852K
AGIO icon
80
Agios Pharmaceuticals
AGIO
$1.93B
$1M 0.13%
+15,000
New +$901K
RGLS
81
DELISTED
Regulus Therapeutics
RGLS
$725K 0.09%
4,833
-114
-2% -$14.3K
ADVM
82
DELISTED
Adverum Biotechnologies
ADVM
$562K 0.07%
15,401
– –
JPM icon
83
JPMorgan Chase
JPM
$950B
$539K 0.07%
5,641
+804
+17% +$74.1K
HAL icon
84
Halliburton
HAL
$26.6B
$513K 0.07%
11,144
+3,426
+44% +$144K
WFC icon
85
Wells Fargo
WFC
$264B
$477K 0.06%
8,653
+1,348
+18% +$71.6K
XOM icon
86
ExxonMobil
XOM
$634B
$467K 0.06%
5,696
+873
+18% +$69.3K
PFE icon
87
Pfizer
PFE
$153B
$372K 0.05%
10,985
-442,680
-98% -$14.2M
MSFT icon
88
Microsoft
MSFT
$3.71T
$357K 0.05%
4,793
– –
F icon
89
Ford
F
$55.7B
$340K 0.04%
28,404
– –
BUD icon
90
AB InBev
BUD
$165B
$335K 0.04%
2,806
– –
GEN icon
91
Gen Digital
GEN
$17.5B
$307K 0.04%
+9,359
New +$285K
QCOM icon
92
Qualcomm
QCOM
$176B
$278K 0.04%
5,368
– –
IBM icon
93
IBM
IBM
$224B
$256K 0.03%
1,847
– –
ACAD icon
94
Acadia Pharmaceuticals
ACAD
$5.03B
– –
-30,000
Closed -$837K
AMGN icon
95
Amgen
AMGN
$222B
– –
-35,000
Closed -$6.03M
ATXS
96
DELISTED
Astria Therapeutics
ATXS
– –
-5,179
Closed -$441K
CAH icon
97
Cardinal Health
CAH
$55.4B
– –
-55,000
Closed -$4.29M
DVA icon
98
DaVita
DVA
$11.7B
– –
-55,000
Closed -$3.56M
HALO icon
99
Halozyme
HALO
$12.2B
– –
-120,000
Closed -$1.54M
HOLX
100
DELISTED
Hologic
HOLX
– –
-70,000
Closed -$3.18M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rhenman & Partners Asset Management held 120 positions worth $783M, up 12% from $696M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $43.3M of net new capital in Q3 2017, opening 12 new positions and adding to 45 existing holdings. Its largest new stake was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Pfizer, an estimated $14.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2017 buy was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.
  • Rhenman & Partners Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $12.8M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2017 reduction was Pfizer, cutting an estimated $14.2M.
  • Rhenman & Partners Asset Management fully exited NeuroDerm Ltd. Ordinary Shares in Q3 2017, selling an estimated $13.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $783M portfolio in Q3 2017.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 26 in Q3 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $783M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.